2 completed, 1 terminated, 1 unknown. 2 Phase 3, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Unknown 1 |
| Phase 2 | 1 | Completed 1 |
Follow InDex Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis Cobitolimod 250 mg, Cobitolimod 500 mg, Placebo - Ulcerative Colitis | Phase 3 | Terminated | InDex Pharmaceuticals | 171 | 2021-11-24 | 2023-12-27 |
| Pharmacokinetics of Cobitolimod Enemas in Participants With Active Ulcerative Colitis Cobitolimod 500mg - Ulcerative Colitis | Phase 1 | Unknown | InDex Pharmaceuticals | 6 | 2021-11-22 | 2022-06-10 |
| The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis cobitolimod, Placebo - Ulcerative Colitis | Phase 2 | Completed | InDex Pharmaceuticals | 213 | 2017-06-21 | 2021-02-01 |
| The Efficacy and Safety of Cobitolimod (Kappaproct®) in Chronic Active Treatment Refractory Ulcerative Colitis Patients Cobitolimod, Placebo - Colitis, Ulcerative | Phase 3 | Completed | InDex Pharmaceuticals | 131 | 2011-12-01 | 2023-01-10 |
Colitis, Ulcerative (4) · Gastrointestinal Diseases (3) · Inflammatory Bowel Diseases (3)
cobitolimod (4) · DIMS0150 (1)
France (3) · Germany (3) · Hungary (3) · Poland (3) · Sweden (3) · Czechia (2) · Italy (2) · Serbia (2) · United Kingdom (2) · Australia (1) · Austria (1) · Belgium (1) · Bosnia and Herzegovina (1) · Brazil (1) · Canada (1)
Christopher Hawkey, MD (1) · Johan Levin (1) · Raja Atreya (1) · Raja Atreya, Professor (1)
2016 (1)